至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib.

Appl Microbiol Biotechnol. 2019; 
Dong Y, Lin Y, Gao X, Zhao Y, Wan Z, Wang H, Wei M, Chen X, Qin W, Yang G, Liu L.
Products/Services Used Details Operation
Custom Vector Construction … Relative expression was calculated with the 2 −ΔΔ Ct method (Nolan et al. 2006). Luciferase reporter assay. ABCG2 3′UTR (2488–4554) was cloned into the psiCHECK™-2 vectors (Promega, Madison, Wisconsin, USA) by Genscript (Nanjing, China) … Get A Quote

摘要

Imatinib resistance remains the biggest hurdle for the treatment of chronic myeloid leukemia (CML), with the underlying mechanisms not fully understood. In this study, we found that miR328 significantly and strikingly decreased among other miRNA candidates during the induction of imatinib resistance. Overexpression of miR328 sensitized resistant cells to imatinib via post-transcriptionally decreasing ABCG2 expression, while miR328 knockdown conferred imatinib resistance in parental K562 cells. Moreover, miR328 was found selectively degraded in the lysosomes of K562R cells, as inhibition of lysosome with chloroquine restored miR328 expression and increased sensitivity to imatinib. Moreover, delivery of alkalized... More

关键词

Chronic myeloid leukemia; Exosome delivery; Imatinib resistance; Lysosomal degradation; miR328